# A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

> **NCT00952198** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 128 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ARRY-403, glucokinase activator; oral
- **DRUG:** Placebo; oral

## Key facts

- **NCT ID:** NCT00952198
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952198, "A Safety Study of ARRY-403 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00952198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*